Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treating IgA nephropathy with atrasentan

A technology for atrasentan and nephropathy, which is applied in the field of treating IgA nephropathy with atrasentan, and can solve problems such as reducing the quality of life

Pending Publication Date: 2021-08-17
CHINOOK THERAPEUTICS INC
View PDF15 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

During this time, in addition to a decline in kidney function, patients experience a variety of symptoms that can significantly reduce their quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating IgA nephropathy with atrasentan
  • Method of treating IgA nephropathy with atrasentan
  • Method of treating IgA nephropathy with atrasentan

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0594] Embodiment 1. A method of inhibiting mesangial cell activation in a subject with IgA nephropathy comprising administering to the subject a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof;

[0595] Wherein the subject has not been previously diagnosed with one or more of: diabetic nephropathy, HIV / AIDS or acute renal failure.

Embodiment approach 2

[0596] Embodiment 2. A method of treating IgA nephropathy comprising administering to a subject in need thereof a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof;

[0597] Wherein the subject has not been previously diagnosed with one or more of: diabetic nephropathy, HIV / AIDS or acute renal failure.

Embodiment approach 3

[0598] Embodiment 3. A method of treating IgA nephropathy comprising administering to a subject in need thereof a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof;

[0599] Wherein the subject does not suffer from one or more of the following: diabetic nephropathy, HIV / AIDS or acute renal failure.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein is a method of treating IgA nephropathy comprising administering to a subject in need thereof a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof. Also provided herein is a method of reducing kidney inflammation and / or fibrosis, reducing hematuria onset, stabilizing eGFR, reducing the number of disease attacks associated with IgA-nephropathy, delaying ESRD attacks, reducing proteinuria, and reducing fatigue in a subject suffering from IgA nephropathy, comprising administering to the subject a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof. In some embodiments, a subject is not previously diagnosed with one or more of diabetic nephropathy, HIV / AIDS, HIV-related nephropathy, prostate cancer, or acute renal failure.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 62 / 949,115, filed December 17, 2019, U.S. Provisional Application No. 63 / 005,003, filed April 3, 2020, U.S. Provisional Application No. 63 / 072,699, the priority of U.S. Provisional Application No. 63 / 084,739, filed September 29, 2020, and U.S. Provisional Application No. 63 / 125,205, filed December 14, 2020, incorporated by reference in their entirety. Background technique [0003] IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Aberrant IgA1 glycosylation results in elevated serum levels of galactose-deficient IgA1 (Gd-IgA1), which are recognized by glycan-specific IgA and IgG autoantibodies. Aggregates of immune complexes form and / or deposit in situ in the glomerular mesangium. This promotes the proliferation of mesangial cells, increases the synthesis of extracellular matrix proteins, cytokines, chemokines, and promotes the infil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P13/12A61K45/06A61P7/12
CPCA61K31/4025A61P31/12A61P7/12A61P13/12A61K45/06A61K31/70A61K2300/00A61K31/41A61K31/7042A61K31/472C07D405/04
Inventor P.T.弗罗里希A.J.金C.拉马钱德拉S.B.诺恩伯格
Owner CHINOOK THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com